TOPLINE: Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) detected metastatic disease in 46% of patients with high-risk prostate cancer previously classified as nonmetastatic by conventional imaging. Results were positive in 84% of patients, with polymetastatic disease found in 24% of cases. METHODOLOGY: Recurrent nonmetastatic hormone-sensitive prostate cancer is characterized by increasing prostate-specific antigen (PSA) levels while …
Leave a Comment Leave a Comment
